Propanc Biopharma Reports $8.9 Million Net Loss for Six Months Ending December 31, 2025

Propanc Biopharma, Inc. reported its financial results for the six months ending December 31, 2025, revealing a net loss of $8.9 million, a significant increase from a net loss of $784,493 during the same period in 2024. The company did not generate any revenue in either fiscal period. Operating expenses surged to $8.3 million for the six months ended December 31, 2025, compared to $504,172 in the prior year, primarily driven by increased administrative costs, which rose to $8.2 million from $374,352. The company’s total assets decreased to $15.1 million from $19.6 million as of June 30, 2025, largely due to a reduction in prepaid expenses.

In terms of liabilities, Propanc's total liabilities decreased to $3.7 million from $5.7 million in the previous fiscal period. This reduction was attributed to a decrease in accounts payable and accrued expenses, which fell from $1.2 million and $1.5 million, respectively, to $957,483 and $860,463. The company also reported a notable change in its stockholders' equity, which declined to $10.5 million from $13.9 million, reflecting the impact of the net loss and a deemed dividend related to the issuance of Series C Preferred Stock.

Strategically, Propanc Biopharma has focused on advancing its lead product candidate, PRP, which is designed to enhance the anti-cancer effects of multiple enzymes. The company has been actively pursuing patent protections, with 85 patents granted or accepted globally, and aims to expand its market presence as it progresses through preclinical development. The company’s operational focus remains on developing non-toxic, long-term therapies for cancer survivors, although it has not yet launched any products commercially.

The company’s cash position improved significantly, with cash and cash equivalents rising to $561,237 from $12,088 at the end of the previous fiscal period. This increase was primarily due to financing activities, including proceeds from the issuance of common stock and convertible promissory notes. Propanc's management indicated that the company is committed to advancing its product development and is exploring additional funding opportunities to support its operations and growth initiatives.

Looking ahead, Propanc Biopharma anticipates that its ongoing research and development efforts will lead to advancements in its product pipeline. The company remains focused on establishing a global market for its technologies and aims to enhance its financial position through strategic partnerships and potential future offerings. However, the company cautioned that its results for the six months ended December 31, 2025, may not be indicative of future performance, as it continues to navigate the complexities of the biotechnology sector.